Regeneron Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Regeneron Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Regeneron Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Regeneron Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreRegeneron Pharmaceuticals Inc (Regeneron) is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. Its major products and product candidates are developed related to the therapy areas of eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron develops products using its Trap and VelociSuite technology platforms. The company offers its products to pharmacies, hospitals, government agencies, physicians, and other healthcare providers through the brands EYLEA, Dupixent, Libtayo, Praluent, Evkeeza, and Inmazeb, among others, in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK. It operates manufacturing units in the US and Ireland. Regeneron is headquartered in Tarrytown, New York, the US.
Headquarters
United States of America
Address
777 Old Saw Mill River Road, Tarrytown, New York, 10591
Website
www.regeneron.com
Telephone
1 914 8477000
No of Employees
15,410
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
REGN (NASD)
Revenue (2025)
$14.3B
1%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
2.1%
(2025 vs 2024)
Market Cap*
$79.2B
Net Profit Margin (2025)
XYZ
1.1%
(2025 vs 2024)
* As of and is in US$
Regeneron Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Eylea (Aflibercept) Injection | Arcalyst |
| Arcalyst (Rilonacept) | Evkeeza |
| Praluent (alirocumab) Injection | Eylea |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In December, the company partnered with Tessera Therapeutics, Inc. to develop and commercialize TSRA-196, Tessera’s investigational in vivo Gene Writing program to treat alpha-1 antitrypsin deficiency, an inherited monogenic disease that can affect the lungs, liver, or both organs. |
| 2025 | Regulatory Approval | In December, the company and Sanofi secured approval from the Ministry of Health, Labour and Welfare for Dupixent (dupilumab) to treat patients with bronchial asthma in children aged 6 to 11 years. |
| 2025 | Regulatory Approval | In November, the company and Sanofi secured approval from the European Commission for Dupixent (dupilumab) to treat patients with moderate-to-severe chronic spontaneous urticaria in adult and adolescent patients 12 years and above with inadequate response to histamine-1 antihistamines (H1AH). |
Competitor Comparison
| Key Parameters | Regeneron Pharmaceuticals Inc | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Tarrytown | Indianapolis | Rahway | New York City | North Chicago |
| State/Province | New York | Indiana | New Jersey | New York | Illinois |
| No. of Employees | 15,410 | 47,000 | 73,000 | 75,000 | 57,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Leonard S. Schleifer, MD, PhD | Co Chairman; Chief Executive Officer; President | Executive Board | 2023 | 72 |
| George D. Yancopoulos, MD, PhD | Co-Chairman; Chief Scientific Officer; President | Executive Board | 2023 | 65 |
| Christopher Fenimore | Chief Financial Officer; Executive Vice President - Finance | Senior Management | 2025 | 53 |
| Bob McCowan | Senior Vice President - IT; Chief Information Officer | Senior Management | 2018 | - |
| Melissa Lozner | Senior Vice President; Chief Compliance Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer